Analytical performance validation of a coronary heart disease risk assessment multi-analyte proteomic test

Nolan N, Tee L, Vijayakumar S, Burazor I, Hytopoulos E, Biggs WH, Beggs M, French C, Harrington DS.
Journal   Expert Opin Med Diagn
Species  
Analytes Measured   CTACK , HGF , IL-16 , MCP-3
Matrix Tested   Serum
Year   2012
Volume  
Page Numbers  
Application   Cytokines and Chemokines
Abstract
Background: Coronary heart disease (CHD) remains prevalent despite efforts to improve CHD risk assessment. The authors developed a multi-analyte immunoassay-based CHD risk assessment (CHDRA) algorithm, clinically validated in a multicenter study, to improve CHDRA in intermediate risk individuals.

Objective: Clinical laboratory validation of the CHDRA biomarker assays' analytical performance.

Methods: Multiplexed immunoassay panels developed for the seven CHDRA assays were evaluated with donor sera in a clinical laboratory. Specificity, sensitivity, interfering substances and reproducibility of the CHDRA assays, along with the effects of pre-analytical specimen processing, were evaluated.

Results: Analytical measurements of the CHDRA panel proteins (CTACK, Eotaxin, Fas Ligand, HGF, IL-16, MCP-3 and sFas) exhibited acceptable accuracy (80 – 120%), cross-reactivity (< 1%), interference (< 30% at high concentrations of bilirubin, lipids, hemoglobin and HAMA), sensitivity and reproducibility (< 20% CV across multiple runs, operators and instruments). Recoveries from donor sera subjected to typical clinical laboratory pre-analytical conditions were within 80 – 120%. The pre-analytical variables did not substantively impact the CHDRA scores.

Conclusions: The CHDRA panel analytical validation in a clinical laboratory meets or exceeds the specifications established during the clinical utility studies. Risk score reproducibility across multiple test scenarios suggests the assays are not susceptible to clinical laboratory pre-analytical and analytical variation.

Related Products

U-PLEX Alzheimer's Disease Combo 1 (human)
Eotaxin, IL-1α, IL-12/IL-23p40, IL-16, IL-17A, MCP-1, MDC, MIF, SDF-1α, YKL-40 | Human
Multiplex
NEW
U-PLEX TH17 Combo 3 (mouse)
IL-16, IL-17A, IL-17C, IL-17E/IL-25, IL-17F, IL-21, IL-22, IL-23, IL-31, MIP-3α | Mouse
Multiplex
NEW
U-PLEX Multiple Sclerosis Combo 1 (human)
CTACK, Fractalkine, GRO-α, IL-7, IL-12/IL-23p40, IP-10, MCP-1, MIP-1β, MIP-3α | Human
Multiplex
NEW
R-PLEX Mouse HGF Antibody Set
HGF | Mouse
R-PLEX Mouse HGF Assay
HGF | Mouse
Singleplex
U-PLEX Mouse IL-16 384-Well Assay
IL-16 | Mouse
Singleplex
U-PLEX NHP IL-16 384-Well Assay
IL-16 | Non-human primate
Singleplex
U-PLEX NHP CTACK 384-Well Assay
CTACK | Non-human primate
Singleplex
U-PLEX Human CTACK 384-Well Assay
CTACK | Human
Singleplex
U-PLEX Human IL-16 384-Well Assay
IL-16 | Human
Singleplex
U-PLEX Human MCP-3 384-Well Assay
MCP-3 | Human
Singleplex
R-PLEX Human HGF Assay
HGF | Human
Singleplex
R-PLEX Human HGF Antibody Set
HGF | Human
U-PLEX Human MCP-3 Antibody Set
MCP-3 | Human
U-PLEX Human IL-16 Antibody Set
IL-16 | Human
U-PLEX Human CTACK Antibody Set
CTACK | Human
Cytokine Panel 1 Human Control Pack
GM-CSF, IL-1α, IL-5, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-17A, TNF-β, VEGF-A | Human
Human IL-16 Antibody
IL-16
Browse Our Products

By Analytes
By Applications
Search
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters